Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies (2014)

Peer-Reviewed Study · Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J · March 2014

Stein L et al., 2014-03: The two identical pivotal phase III trials of once-daily ivermectin 1% cream for papulopustular rosacea, with about 38-40% of treated subjects clear or almost clear at 12 weeks versus 12-19% on vehicle.

Ivermectin was superior to vehicle in terms of reduction from baseline in inflammatory lesion counts (76.0% and 75.0% vs 50.0% for both vehicle groups, respectively).

Stein L et al., 2014-03: The two identical pivotal phase III trials of once-daily ivermectin 1% cream for papulopustular rosacea, with about 38-40% of treated subjects clear or almost clear at 12 weeks versus 12-19% on vehicle. Two identically designed randomized double-blind vehicle-controlled phase III trials; N=1371 (per the product label, IVE-03); 12 weeks of once-daily cream; co-primary endpoints IGA success and inflammatory lesion count change. IGA success 38.4% and 40.1% vs 11.6% and 18.8% (both P<.001); lesion counts reduced 76.0% and 75.0% vs 50.0%. Comparator: vehicle cream. Funder not stated in the abstract; the product is Galderma's Soolantra. Study type: randomized trial.